Tibsovo Approval Expanded for Newly Diagnosed IDH1-Mutated AML
The approval was based on data from the phase 3 AGILE trial.
The approval was based on data from the phase 3 AGILE trial.
Researchers sought to determine whether adding pevonedistat to azacitidine would improve outcomes for patients with higher-risk MDS, CMML, or AML.
Researchers sought to determine whether guadecitabine would have an overall survival benefit for patients with relapsed/refractory acute myeloid leukemia.
Patients received up to 8 cycles of AZA and up to 3 cycle of DLI with increasing T cell dosages.
Eight patients had a complete response within 1 month of infusion.
Researchers sought to determine whether patients with AML were being undertreated due to patient fear about side effects to treatment.
Researchers sought to determine whether first-line aspacytarabine would be safe and effective in patients with AML who cannot tolerate chemotherapy.
Patients with AML or MDS were significantly more likely to die from COVID-19 vs other HMs. Most treatments did not improve survival outcomes — except corticosteroids.
Now that the phase 2 dose is established, a randomization cohort will test the efficacy of the treatments in the LACEWING trial.
Census tract affluence, disadvantage, and segregation were all significant predictors of leukemia-related death.